In line Q4; opportune time to capitalise the Swiss giant’s sell-off
02/02/23 -"Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In Oncology, newer drugs largely compensated for ..."
Pages
70
Language
English
Published on
02/02/23
You may also be interested by these reports :
20/03/23
The positive recommendation is reiterated, underpinned by the firm’s strong pipeline, healthy progress on clinical trials and the promising market ...
20/03/23
Supported by Novartis’ ongoing profitability improvements and healthy growth potential for the firm’s marketed as well as the pipeline drugs ...
20/03/23
Our positive recommendation on UCB is reiterated, backed by the strong growth potential of its newer crop of drugs and late-stage pipeline, and ...
15/03/23
We have fully integrated 2022 and slightly adjusted our estimates. The 2022 EPS has been impacted by a technicality as we have earmarked the proceeds ...